NRG Oncology Limited-Stage Small Cell Lung Cancer Trial Participant Interviewed on his Journey

August 13 2021

Advocate Aurora Research Institute recently interviewed Ray Harrison, a United States Marine Corp veteran and family man, on his experiences through his journey with limited-stage small cell lung cancer (LS-SCLC). Ray offered readers a viewpoint of his journey from diagnosis through his current treatment on the National Cancer Institute-sponsored, NRG Oncology-led clinical trial, and the strength provided to him by his grandson Caynen.

The NRG-LU005 study that Ray is participating in evaluates whether doctors can lower the chance of LS-SCLC growing or spreading using the immunotherapy drug atezolizumab along with the standard chemotherapy and radiation therapy for this type of disease.

“If someone will eventually benefit from this, if I can help someone else, I won,” – Ray Harrison

The full interview can be found on pages 25-26 of the Advocate Aurora Research Institute 2020 Annual Report

Click here for the NRG-LU005 webpage with more information on this trial

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.